# Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients

Study · id `cardio:ct-nct03946514` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03946514](<https://clinicaltrials.gov/study/NCT03946514>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03946514

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT03946514. Randomized; no masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2024-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT03946514, source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)
- Started: 2018-09-01 (actual) (ClinicalTrials.gov record NCT03946514, source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)
- Primary completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT03946514, source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)
- Completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT03946514, source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03946514, source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03946514-2025-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients
- Condition: Hypertension
- Intervention (Drug): losartan/hydrochlorothiazide
- Intervention (Drug): amlodipine/hydrochlorothiazide
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

## Provenance

Content hash: 3dd09cc817b625db712633c16e6f0d5744e3ae04039a514a02ad1c1f768683b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
